Relevance of genetic variants of the bitter receptor TAS2R38 for the severity of the course of a COVID-19 disease-pilot-study

Relevance of genetic variants of the bitter receptor TAS2R38 for the severity of the course of a COVID-19 disease-pilot-study - COVTAS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027918

Enrollment

316

Registered

2022-10-31

Start date

2022-01-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 LONGCOVID

Interventions

Group 1: Determination of TAS2R38 genotype by sequencing on a buccal mucosal swab (categorical with three expressions) One-time data collection by means of a questionnaire on the severity of the disea

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: - 18-85 years old with - Mild or severe history of COVID-19 disease, proven by positive PCR- test for SARS-CoV-2.

Exclusion criteria

Exclusion criteria: - Vaccination against Sars-CoV-2 before infection. - Persons with mental retardation, dementia and existing Pregnancy.

Design outcomes

Primary

Measure	Time frame
Determination of TAS2R38 genotype by sequencing on a buccal mucosal swab (categorical with three expressions) One-time data collection by means of a questionnaire on the severity of the disease. Correlation between genetic variant of TAS2R38 gene (sequencing SNP) and severity of Covid-19 disease (questionnaire).	—

Secondary

Measure	Time frame
- Verification of perception of "bitter" using commercially available test strips (expression) - Symptoms of COVID-19 disease, including "long-COVID" symptomatology - Known risk factors for progression to COVID-19 disease: Advanced age, cardiovascular disease, diabetes mellitus, organ transplantation, cancer, stroke, bronchial asthma or chronic obstructive pulmonary disease (COPD), chronic liver or kidney disease, obesity (body mass index,BMI = 40), or smoking (Rommel, von der Lippe et al. 2021), determined by questionnaire.	—

Measure

Time frame

- Verification of perception of "bitter" using commercially available test strips (expression) - Symptoms of COVID-19 disease, including "long-COVID" symptomatology - Known risk factors for progression to COVID-19 disease: Advanced age, cardiovascular disease, diabetes mellitus, organ transplantation, cancer, stroke, bronchial asthma or chronic obstructive pulmonary disease (COPD), chronic liver or kidney disease, obesity (body mass index,BMI = 40), or smoking (Rommel, von der Lippe et al. 2021), determined by questionnaire.

—

Countries

Germany

Contacts

Public ContactSimon Spöhr

Uniklinik Freiburg, Molekulare Präventivmedizin

simon.spöhr@uniklinik-freiburg.de076127083590

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026